PD-1/PD-L1 Inhibitors: The First Major Wave of Immuno-Oncology

  • ID: 4421397
  • Report
  • 47 pages
  • Datamonitor Healthcare
1 of 3
PD-1/PD-L1 Inhibitors: The First Major Wave of Immuno-Oncology

Since Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) first gained Japanese regulatory approval for the treatment of metastatic melanoma in July 2014, programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors have grown to become the leading class of immunotherapies in oncology worldwide. Sales of the PD-1/PD-L1 therapy class have grown from $84m in 2014 to $6,292m in 2016, with five PD-1/PD-L1 inhibitors currently approved across a variety of tumor indications. Despite the success of these products, developers continue to face clinical and commercial challenges. Nonetheless, the broad applicability and strong initial success of PD-1/PD-L1 inhibitors in oncology means that companies are actively seeking ways to differentiate their products and increase their market share.

Note: The analyst Dustin Phan presented these slides in Tokyo and Osaka during July 2017.
Note: Product cover images may vary from those shown
2 of 3
1 Overview of the current immuno-oncology market
  • Ongoing developments in the PD-1/PD-L1 therapy space
2 Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical)
  • Keytruda (pembrolizumab; Merck & Co)
  • Tecentriq (atezolizumab; Roche/Chugai)
  • Imfinzi (durvalumab; AstraZeneca)
  • Bavencio (avelumab; Merck KGaA/Pfizer)
3 Challenges with PD-1/PD-L1 inhibitor development and treatment

4 An examination of:
  • Non-small cell lung cancer (NSCLC)
  • Bladder cancer
5 Looking forward: the future of immuno-oncology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll